|
WO1998041229A1
(en)
*
|
1997-03-19 |
1998-09-24 |
F. Hoffmann-La Roche Ag |
USE OF IL-12p40 AS IMMUNOSTIMULANT
|
|
WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
ATE329622T1
(de)
*
|
1998-04-15 |
2006-07-15 |
Lexigen Pharm Corp |
Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
|
|
WO2000015249A1
(en)
*
|
1998-09-15 |
2000-03-23 |
Genetics Institute, Inc. |
Treatment of kaposi's sarcoma with il-12
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
US20030190305A1
(en)
*
|
1999-09-15 |
2003-10-09 |
Wyeth And National Institutes Of Health |
Treatment of Kaposi's sarcoma with IL-12
|
|
DE60017165T2
(de)
|
1999-10-11 |
2006-01-12 |
Felton International, Inc., Lenexa |
Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
|
|
US7074210B2
(en)
*
|
1999-10-11 |
2006-07-11 |
Felton International, Inc. |
Universal protector cap with auto-disable features for needle-free injectors
|
|
ATE409494T1
(de)
*
|
1999-10-29 |
2008-10-15 |
Anges Mg Inc |
Gentherapie für diabetische ischämie
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
US7887506B1
(en)
|
1999-11-23 |
2011-02-15 |
Pulse Needlefree Systems, Inc. |
Safety mechanism to prevent accidental patient injection and methods of same
|
|
US6770054B1
(en)
|
1999-11-23 |
2004-08-03 |
Felton International, Inc. |
Injector assembly with driving means and locking means
|
|
US7115712B1
(en)
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US20020120228A1
(en)
*
|
2000-06-08 |
2002-08-29 |
Yuh-Fun Maa |
Powder compositions
|
|
US20040213798A1
(en)
*
|
2000-06-08 |
2004-10-28 |
Powderject Vaccines, Inc. |
Spray-dried alum compositions
|
|
US7517526B2
(en)
*
|
2000-06-29 |
2009-04-14 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
US7255865B2
(en)
*
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
US20020086036A1
(en)
|
2000-12-05 |
2002-07-04 |
Allergan Sales, Inc. |
Methods for treating hyperhidrosis
|
|
EP1366067B1
(en)
*
|
2001-03-07 |
2012-09-26 |
Merck Patent GmbH |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
DE60239454D1
(de)
*
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
|
CA2349506C
(en)
*
|
2001-06-14 |
2009-12-08 |
Duke University |
A method for selective expression of therapeutic genes by hyperthermia
|
|
ATE542137T1
(de)
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
|
BRPI0317376B8
(pt)
*
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
|
JP2007517506A
(ja)
*
|
2004-01-05 |
2007-07-05 |
イーエムディー・レキシゲン・リサーチ・センター・コーポレーション |
標的化用化合物
|
|
PT1966238E
(pt)
*
|
2005-12-30 |
2012-07-31 |
Merck Patent Gmbh |
Uso de hsp70 como um regulador de atividade enzimática
|
|
WO2007084364A2
(en)
*
|
2006-01-13 |
2007-07-26 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Improved il-12 for expression in mammalian cells
|
|
HUE035406T2
(en)
*
|
2007-10-08 |
2018-05-02 |
Intrexon Corp |
Engineered dendritic cells and uses for the treatment of cancer
|
|
RU2573912C2
(ru)
|
2008-10-08 |
2016-01-27 |
Интрексон Корпорейшн |
Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
|
|
US8556882B2
(en)
|
2009-04-30 |
2013-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
|
US20110014228A1
(en)
*
|
2009-06-15 |
2011-01-20 |
New York University |
Il23 modified viral vector for recombinant vaccines and tumor treatment
|
|
KR20220159479A
(ko)
|
2016-05-18 |
2022-12-02 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|